23 May 2022 , 08:17 PM
Full year FY22 revenues were up 28.6% at Rs8,960crore. For Q4FY22, Divi witnessed growth across its API and nutraceutical business. Net cash flows from operations were stable.
During the year, the company capitalized assets of Rs935 crore to convert into capitalized assets. Capital WIP (work in progress) amounted to Rs470 crore.
The company saw improvement in its EBIT performance across active pharma ingredients (APIs) and also nutraceuticals.
Net margins were 35.52% in Q4FY22 quarter compared to 28.07% in Q4FY21. NPM was lower compared to 36.19% in Q3FY22.
The company board declared dividend of Rs30 per share or 1500% on par value of Rs2 per share, subject to shareholder approval for fiscal year 2021-22.
Financial highlights for Mar-22 compared yoy and sequentially
Divi’s Laboratories | |||||
Rs in Crore | Mar-22 | Mar-21 | YOY | Dec-21 | QOQ |
Total Income (Rs cr) | ₹ 2,518.44 | ₹ 1,788.19 | 40.84% | ₹ 2,493.24 | 1.01% |
Net Profit (Rs cr) | ₹ 894.64 | ₹ 502.02 | 78.21% | ₹ 902.24 | -0.84% |
Diluted EPS (Rs) | ₹ 33.70 | ₹ 18.91 | ₹ 33.99 | ||
Net Margins | 35.52% | 28.07% | 36.19% |
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.